IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable
IRIDEX (NASDAQ:IRIX) Frequently Asked Questions
What is IRIDEX's stock symbol?
IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."
How were IRIDEX's earnings last quarter?
IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Thursday, November, 7th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.05. The medical equipment provider earned $10.66 million during the quarter, compared to analysts' expectations of $10.08 million. View IRIDEX's Earnings History.
When is IRIDEX's next earnings date?
What guidance has IRIDEX issued on next quarter's earnings?
IRIDEX issued an update on its fourth quarter 2019
After-Hours earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $11.6-11.8 million, compared to the consensus revenue estimate of $10.88 million.
Has IRIDEX been receiving favorable news coverage?
News stories about IRIX stock have been trending neutral on Sunday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IRIDEX earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for IRIDEX.
Are investors shorting IRIDEX?
IRIDEX saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 78,800 shares, a decrease of 12.0% from the January 15th total of 89,500 shares. Based on an average daily trading volume, of 70,900 shares, the short-interest ratio is currently 1.1 days. Approximately 0.7% of the shares of the stock are sold short. View IRIDEX's Current Options Chain.
What other stocks do shareholders of IRIDEX own?
Who are IRIDEX's key executives?
IRIDEX's management team includes the folowing people:
- Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 70)
- Dr. George R. Marcellino, VP of Clinical Affairs (Age 70)
- Mr. Romeo R. Dizon, VP of Fin.
- Ms. Leigh Salvo, Head of Investor Relations
- Mr. Timothy D. Buckley, VP of Marketing & North American Sales (Age 44)
Who are IRIDEX's major shareholders?
IRIDEX's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.43%), Isthmus Partners LLC (1.54%), Perkins Capital Management Inc. (0.39%), Gabelli Funds LLC (0.11%) and Blair William & Co. IL (0.09%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, Robert Earle Grove, Romeo R Dizon, Scott Shuda and William M Moore. View Institutional Ownership Trends for IRIDEX.
Which institutional investors are selling IRIDEX stock?
Which institutional investors are buying IRIDEX stock?
IRIX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Isthmus Partners LLC and Perkins Capital Management Inc.. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon, Robert Earle Grove, Scott Shuda and William M Moore. View Insider Buying and Selling for IRIDEX.
How do I buy shares of IRIDEX?
Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IRIDEX's stock price today?
One share of IRIX stock can currently be purchased for approximately $3.31.
MarketBeat Community Rating for IRIDEX (NASDAQ IRIX)
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
